检索范围:
排序: 展示方式:
《医学前沿(英文)》 页码 805-822 doi: 10.1007/s11684-023-1025-7
关键词: CTLA-4 PD-1 PD-L1 immune checkpoint blockade (ICB) metabolic reprogramming combined tumor therapeutic strategies
Molecular mechanisms and therapeutic strategies of vulnerable atherosclerotic plaques
Wen-Qiang CHEN MD, Yun ZHANG MD, PhD, FACC,
《医学前沿(英文)》 2010年 第4卷 第1期 页码 36-42 doi: 10.1007/s11684-010-0020-y
关键词: vulnerable plaque animal models mechani-sm detection treatment
Guangbiao Zhou, Saijuan Chen, Zhu Chen
《医学前沿(英文)》 2020年 第14卷 第2期 页码 117-125 doi: 10.1007/s11684-020-0773-x
关键词: COVID-19 SARS-CoV-2 pathogenesis evidence-based medicine control and therapeutic strategies
REN Peitu, LU Baochun, RUAN Xinxian, CHEN Zhiliang, MA Yuliang, FU Hong
《医学前沿(英文)》 2008年 第2卷 第2期 页码 143-146 doi: 10.1007/s11684-008-0027-9
TAN Guang, WANG Zhongyu, CHE Luanqing, YIN Shuo
《医学前沿(英文)》 2007年 第1卷 第1期 页码 41-45 doi: 10.1007/s11684-007-0008-4
Circulating microRNAs in cardiovascular diseases: from biomarkers to therapeutic targets
null
《医学前沿(英文)》 2014年 第8卷 第4期 页码 404-418 doi: 10.1007/s11684-014-0379-2
microRNAs (miRNAs) are a class of conserved, short, non-coding RNAs that have important and potent capacities to regulate gene expression at the posttranscriptional level. In the past several years, the aberrant expressions of miRNAs in the cardiovascular system have been widely reported, and the crucial roles of some special miRNAs in heart development and pathophysiology of various cardiovascular diseases have been gradually recognized. Recently, it was discovered that miRNAs are presented in peripheral circulation abundantly and stably. This has raised the possibility of using circulating miRNAs as biomarkers for diseases. Furthermore, some studies demonstrated that circulating miRNAs may serve as novel extracellular communicators of cell-cell communication. These discoveries not only reveal the functions of circulating miRNAs in cardiovascular system but also inform the development of miRNAs therapeutic strategies. In this review, we discuss the potential roles of circulating miRNAs in a variety of cardiovascular diseases from biomarkers to therapeutic targets to clearly understand the roles of circulating miRNAs in cardiovascular system.
关键词: microRNA cardiovascular disease biomarkers therapeutic target
Zhaoshi Bao, Yongzhi Wang, Qiangwei Wang, Shengyu Fang, Xia Shan, Jiguang Wang, Tao Jiang
《医学前沿(英文)》 2021年 第15卷 第4期 页码 551-561 doi: 10.1007/s11684-020-0760-2
关键词: glioma evolution mechanism strategies tumor heterogeneity secondary glioma
Brown and beige fat: the metabolic function, induction, and therapeutic potential
null
《医学前沿(英文)》 2015年 第9卷 第2期 页码 162-172 doi: 10.1007/s11684-015-0382-2
Adipose tissue is an important organ for energy homeostasis. White adipose tissue stores energy in the form of triglycerides, whereas brown adipocytes and recently identified beige adipocytes are specialized in dissipating energy by thermogenesis or contribution to dispose glucose and clear triglycerides in blood. The inverse correlation between the brown adipose tissue activity and body mass suggests its protective role against body fat accumulation. Thus, recruitment and activation of brown or beige adipose tissue become particularly appealing targets for increasing energy expenditure. Angiogenesis and sympathetic nerve signals are the fundamental determinants for brown and beige adipose tissue development, as well as for their metabolic functions. Secretary factors including BMPs can induce the development, the activation of brown or beige adipose tissue, which seem to be promising for therapeutic development.
Heterogeneity of the tumor immune microenvironment and clinical interventions
《医学前沿(英文)》 2023年 第17卷 第4期 页码 617-648 doi: 10.1007/s11684-023-1015-9
Proteins moonlighting in tumor metabolism and epigenetics
Lei Lv, Qunying Lei
《医学前沿(英文)》 2021年 第15卷 第3期 页码 383-403 doi: 10.1007/s11684-020-0818-1
Complex interplay between tumor microenvironment and cancer therapy
null
《医学前沿(英文)》 2018年 第12卷 第4期 页码 426-439 doi: 10.1007/s11684-018-0663-7
Tumor microenvironment (TME) is comprised of cellular and non-cellular components that exist within and around the tumor mass. The TME is highly dynamic and its importance in different stages of cancer progression has been well recognized. A growing body of evidence suggests that TME also plays pivotal roles in cancer treatment responses. TME is significantly remodeled upon cancer therapies, and such change either enhances the responses or induces drug resistance. Given the importance of TME in tumor progression and therapy resistance, strategies that remodel TME to improve therapeutic responses are under developing. In this review, we provide an overview of the essential components in TME and the remodeling of TME in response to anti-cancer treatments. We also summarize the strategies that aim to enhance therapeutic efficacy by modulating TME.
关键词: tumor microenvironment therapy response treatment resistance
《医学前沿(英文)》 2023年 第17卷 第4期 页码 699-713 doi: 10.1007/s11684-022-0972-8
关键词: anti-CD19 chimeric antigen receptor T immunotherapy diffuse large B cell lymphoma tumor microenvironment tumor-associated macrophage metabolism
null
《医学前沿(英文)》 2013年 第7卷 第4期 页码 462-476 doi: 10.1007/s11684-013-0270-6
Evaluating the effects of novel drugs on appropriate tumor models has become crucial for developing more effective therapies that target highly tumorigenic and drug-resistant cancer stem cell (CSC) populations. In this study, we demonstrate that a subset of cancer cells with CSC properties may be enriched into tumor spheroids under stem cell conditions from a non-small cell lung cancer cell line. Treating these CSC-like cells with gemcitabine alone and a combination of gemcitabine and the novel CHK1 inhibitor PF-00477736 revealed that PF-00477736 enhances the anti-proliferative effect of gemcitabine against both the parental and the CSC-like cell populations. However, the CSC-like cells exhibited resistance to gemcitabine-induced apoptosis. Collectively, the spheroid-forming CSC-like cells may serve as a model system for understanding the mechanism underlying the drug resistance of CSCs and for guiding the development of better therapies that can inhibit tumor growth and eradicate CSCs.
关键词: drug resistance cancer stem cell checkpoint kinase 1 (CHK1) PF-00477736 lung cancer tumorigenicity
Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives
null
《医学前沿(英文)》 2012年 第6卷 第1期 页码 67-78 doi: 10.1007/s11684-012-0176-8
Antitumor angiogenic therapy has been shown promising in the treatment of several advanced cancers since the approval of the first antiangiogenic drug Avastin in 2004. Although the current antiangiogenic drugs reduce the density of tumor blood vessels and result in tumor shrinkage at the early stage of treatment, recent studies have shown that antiangiogenic therapy has transient and insufficient efficacy, resulting in tumor recurrence in patients after several months of treatment. Blockage of blood and oxygen supplies creates a hypoxic and acidic microenvironment in the tumor tissues, which fosters tumor cells to become more aggressive and metastatic. In 2001, Jain proposed tumor vascular normalization as an alternative approach to treating cancers based on the pioneering work on tumor blood vessels by several other researchers. At present, normalizing the disorganized tumor vasculature, rather than disrupting or blocking them, has emerged as a new option for anticancer therapy. Preclinical and clinical data have shown that tumor vascular normalization using monoclonal antibodies, proteins, peptides, small molecules, and pericytes resulted in decreased tumor size and reduced metastasis. However, current tumor vascular normalizing drugs display moderate anticancer efficacy. Accumulated data have shown that a variety of vasculogenic/angiogenic tumor cells and genes play important roles in tumor neovascularization, growth, and metastasis. Therefore, multiple-targeting of vasculogenic tumor cells and genes may improve the efficacy of tumor vascular normalization. To this end, the combination of antiangiogenic drugs with tumor vascular normalizing therapeutics, as well as the integration of Western medicine with traditional Chinese medicine, may provide a good opportunity for discovering novel tumor vascular normalizing drugs for an effective anticancer therapy.
关键词: angiogenesis vasculogenesis neovascularization tumor vasculature normalization traditional Chinese medicine
Natural killer cell lines in tumor immunotherapy
null
《医学前沿(英文)》 2012年 第6卷 第1期 页码 56-66 doi: 10.1007/s11684-012-0177-7
Natural killer (NK) cells are considered to be critical players in anticancer immunity. However, cancers are able to develop mechanisms to escape NK cell attack or to induce defective NK cells. Current NK cell-based cancer immunotherapy is aimed at overcoming NK cell paralysis through several potential approaches, including activating autologous NK cells, expanding allogeneic NK cells, usage of stable allogeneic NK cell lines and genetically modifying fresh NK cells or NK cell lines. The stable allogeneic NK cell line approach is more practical for quality-control and large-scale production. Additionally, genetically modifying NK cell lines by increasing their expression of cytokines and engineering chimeric tumor antigen receptors could improve their specificity and cytotoxicity. In this review, NK cells in tumor immunotherapy are discussed, and a list of therapeutic NK cell lines currently undergoing preclinical and clinical trials of several kinds of tumors are reviewed.
关键词: natural killer cell natural killer cell line tumor immunotherapy genetic modification
标题 作者 时间 类型 操作
Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanismsand strategies
期刊论文
Molecular mechanisms and therapeutic strategies of vulnerable atherosclerotic plaques
Wen-Qiang CHEN MD, Yun ZHANG MD, PhD, FACC,
期刊论文
Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies
Guangbiao Zhou, Saijuan Chen, Zhu Chen
期刊论文
Therapeutic effect of medical glue combined with the great omentum in severe tunica muscularis injury
REN Peitu, LU Baochun, RUAN Xinxian, CHEN Zhiliang, MA Yuliang, FU Hong
期刊论文
Immunotherapeutic effects on murine pancreatic carcinoma by β-elemene combined with dendritic cells modified
TAN Guang, WANG Zhongyu, CHE Luanqing, YIN Shuo
期刊论文
Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution
Zhaoshi Bao, Yongzhi Wang, Qiangwei Wang, Shengyu Fang, Xia Shan, Jiguang Wang, Tao Jiang
期刊论文
Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma
期刊论文
Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-likecells enriched with tumor spheroids from a non-small cell lung cancer cell line
null
期刊论文
Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives
null
期刊论文